FDA Inspection 1166619 — UPMC Central PA Region IRB
The FDA completed an inspection of UPMC Central PA Region IRB on Mar 11, 2022 in Harrisburg, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 11, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Harrisburg, PA (United States)
Additional Details
IRB